C
CRINETICS PHARMACEUTICALS INC
NASDAQ: CRNX (Crinetics Pharmaceuticals, Inc.)
Kemas kini terakhir: 2 jam lalu51.88
0.56 (1.09%)
| Penutupan Terdahulu | 51.32 |
| Buka | 51.00 |
| Jumlah Dagangan | 679,988 |
| Purata Dagangan (3B) | 1,366,840 |
| Modal Pasaran | 5,318,314,496 |
| Harga / Jualan (P/S) | 3.23 |
| Harga / Buku (P/B) | 5.08 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2026 |
| Margin Operasi (TTM) | -30,860.11% |
| EPS Cair (TTM) | -3.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -43.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.05% |
| Nisbah Semasa (MRQ) | 22.53 |
| Aliran Tunai Operasi (OCF TTM) | -261.57 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -155.77 M |
| Pulangan Atas Aset (ROA TTM) | -20.13% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.84% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Crinetics Pharmaceuticals, Inc. | Menurun | Menaik |
AISkor Stockmoo
1.1
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.5 |
| Purata | 1.13 |
|
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.03% |
| % Dimiliki oleh Institusi | 112.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Price T Rowe Associates Inc /Md/ | 30 Sep 2025 | 5,306,248 |
| Ecor1 Capital, Llc | 30 Sep 2025 | 4,288,120 |
| Janus Henderson Group Plc | 30 Sep 2025 | 3,858,791 |
| Paradigm Biocapital Advisors Lp | 30 Sep 2025 | 2,550,774 |
| Jennison Associates Llc | 30 Sep 2025 | 2,044,734 |
| Point72 Asset Management, L.P. | 30 Sep 2025 | 2,003,333 |
| Siren, L.L.C. | 30 Sep 2025 | 1,688,611 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 105.00 (Citizens, 102.39%) | Beli |
| Median | 80.00 (54.20%) | |
| Rendah | 67.00 (Goldman Sachs, 29.14%) | Beli |
| Purata | 84.00 (61.91%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 51.51 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 12 Jan 2026 | 67.00 (29.14%) | Beli | 55.35 |
| Citizens | 08 Jan 2026 | 105.00 (102.39%) | Beli | 53.24 |
| 07 Nov 2025 | 108.00 (108.17%) | Beli | 40.00 | |
| Morgan Stanley | 06 Jan 2026 | 80.00 (54.20%) | Beli | 45.95 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |